within Pharmacolibrary.Drugs.ATC.N;

model N04BX03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.4,
    Cl             = 0.06666666666666667,
    adminDuration  = 600,
    adminMass      = 0.01,
    adminCount     = 1,
    Vd             = 0.1,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Budipine is an antiparkinsonian agent developed as an adjunct therapy for the treatment of Parkinson's disease. It functions as an NMDA receptor antagonist and has dopaminergic activity. Budipine is not approved for use in many countries and is not widely available on the market today, with limited clinical usage.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters in healthy adult individuals, as no published data with detailed PK modeling for budipine in humans are available.</p><h4>References</h4><ol><li>T H Bethke, M Merz, K Zech, M Seiberling, D Hauschke, H Heinze, W Wurst,Dose linearity and steady state pharmacokinetics of the new antiparkinson agent budipine after oral administration.,International journal of clinical pharmacology and therapeutics,2001<a href='https://pubmed.ncbi.nlm.nih.gov/11430634/'>https://pubmed.ncbi.nlm.nih.gov/11430634/</a></li><li>Manfred Uhr, Martin Ebinger, Marcus C Rosenhagen, Markus T Grauer,The anti-Parkinson drug budipine is exported actively out of the brain by P-glycoprotein in mice.,Neuroscience letters,<a href='https://pubmed.ncbi.nlm.nih.gov/15936515/'>https://pubmed.ncbi.nlm.nih.gov/15936515/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N04BX03;
